tirzepatide cardiovascular outcomes Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology

Possible mechanisms of Tirzepatide's cardiovascular benefits

22.80

★★★★☆4.8 (126)

Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

29.72

★★★★★4.9 (98)

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

23.26

★★★★★5.0 (157)

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

24.59

★★★★★4.7 (84)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

29.33

★★★★★4.9 (203)

❇️ Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 🟠BACKGROUND Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on

25.47

★★★★★5.0 (176)

Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats

20.98

★★★★★4.8 (132)